Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SD-101 + BMS-986178 in advanced solid malignancies
NCT03831295Phase 1Completed
- Start
- Mar 2019
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies, Small Interfering RNA (siRNA), Modified DNA Oligonucleotides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nelitolimod and BMS-986178 in solid tumor (advanced stage). Primary endpoint: Incidence of adverse events of intratumoral injections of study drugs. Started Mar 2019; status: completed.
02
Drugs
nelitolimodBMS-986178
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03831295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03831295.